Literature DB >> 33437678

Performance of Xpert® MTB/RIF and Determine™ TB-LAM Ag in HIV-infected adults in peri-urban sites in Zambia.

M P Kasaro1, O N Chilyabanyama1, N S Shah2, B Muluka1, N Kapata3, A Krüüner1, I Mwaba1, K Kaunda1, W L Coggin2, X J Wen2, G Henostroza1,4, S Reid1,4.   

Abstract

SETTING: Peri-urban health facilities providing HIV and TB care in Zambia.
OBJECTIVE: To evaluate 1) the impact of Xpert® MTB/RIF on time-to-diagnosis, treatment initiation, and outcomes among adult people living with HIV (PLHIV) on antiretroviral therapy (ART); and 2) the diagnostic performance of Xpert and Determine™ TB-LAM Ag assays.
DESIGN: Quasi-experimental study design with the first cohort evaluated per standard-of-care (SOC; first sputum tested using smear microscopy) and the second cohort per an algorithm using Xpert as initial test (intervention phase; IP). Xpert testing was provided onsite in Chongwe District, while samples were transported 5-10 km in Kafue District. TB was confirmed using mycobacterial culture.
RESULTS: Among 1350 PLHIV enrolled, 156 (15.4%) had confirmed TB. Time from TB evaluation to diagnosis (P = 0.018), and from evaluation to treatment initiation (P = 0.03) was significantly shorter for IP than for SOC. There was no difference in all-cause mortality (7.0% vs. 8.6%). TB-LAM Ag showed higher sensitivity with lower CD4 cell count: 81.8% at CD4 < 50 cells/mm3 vs. 31.7% overall.
CONCLUSION: Xpert improved time to diagnosis and treatment initiation, but there was no difference in all-cause mortality. High sensitivity of Determine TB-LAM Ag at lower CD4 count supports increased use in settings providing care to PLHIV, particularly with advanced HIV disease.
© 2020 The Union.

Entities:  

Keywords:  HIV; Mycobacterium tuberculosis; Zambia

Year:  2020        PMID: 33437678      PMCID: PMC7790492          DOI: 10.5588/pha.20.0010

Source DB:  PubMed          Journal:  Public Health Action        ISSN: 2220-8372


  19 in total

1.  Treatment outcomes, diagnostic and therapeutic impact: Xpert vs. smear. A systematic review and meta-analysis.

Authors:  T Agizew; R Boyd; A F Auld; L Payton; S L Pals; P Lekone; V Chihota; A Finlay
Journal:  Int J Tuberc Lung Dis       Date:  2019-01-01       Impact factor: 2.373

Review 2.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

3.  Introducing new tuberculosis diagnostics: the impact of Xpert(®) MTB/RIF testing on case notifications in Nepal.

Authors:  J Creswell; B Rai; R Wali; S Sudrungrot; L M Adhikari; R Pant; S Pyakurel; D Uranw; A J Codlin
Journal:  Int J Tuberc Lung Dis       Date:  2015-05       Impact factor: 2.373

4.  The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF.

Authors:  C F Hanrahan; K Clouse; J Bassett; L Mutunga; K Selibas; W Stevens; L Scott; I Sanne; A Van Rie
Journal:  Int J Tuberc Lung Dis       Date:  2015-07       Impact factor: 2.373

5.  Impact of Point-of-Care Xpert MTB/RIF on Tuberculosis Treatment Initiation. A Cluster-randomized Trial.

Authors:  Richard J Lessells; Graham S Cooke; Nuala McGrath; Mark P Nicol; Marie-Louise Newell; Peter Godfrey-Faussett
Journal:  Am J Respir Crit Care Med       Date:  2017-10-01       Impact factor: 21.405

Review 6.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Hojoon Sohn; Ian Schiller; Lorie A Kloda; Catharina C Boehme; Madhukar Pai; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 7.  Xpert MTB/RIF - why the lack of morbidity and mortality impact in intervention trials?

Authors:  Andrew F Auld; Katherine L Fielding; Ankur Gupta-Wright; Stephen D Lawn
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-09-16       Impact factor: 2.184

8.  Rolling Out Xpert® MTB/RIF for TB Detection in HIV-Infected Populations:An Opportunity for Systems Strengthening.

Authors:  Ishani Pathmanathan; Anand Date; William L Coggin; John Nkengasong; Amy S Piatek; Heather Alexander
Journal:  Afr J Lab Med       Date:  2017-03-31

9.  Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa.

Authors:  Colleen F Hanrahan; Katerina Selibas; Christopher B Deery; Heather Dansey; Kate Clouse; Jean Bassett; Lesley Scott; Wendy Stevens; Ian Sanne; Annelies Van Rie
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

10.  The high burden of tuberculosis (TB) and human immunodeficiency virus (HIV) in a large Zambian prison: a public health alert.

Authors:  German Henostroza; Stephanie M Topp; Sisa Hatwiinda; Katie R Maggard; Winifreda Phiri; Jennifer B Harris; Annika Krüüner; Nathan Kapata; Helen Ayles; Chisela Chileshe; Stewart E Reid
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.